Hesheng Hu

Hesheng Hu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2016 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
HHHesheng Hu
Hesheng Hu
YXYongli Xuan
Yongli Xuan
MXMei Xue
Mei Xue
WCWenjuan Cheng
Wenjuan Cheng
YWYe Wang
Ye Wang
SYSuhua Yan
Suhua Yan
To investigate the effects of semaphorin 3A (sema 3A) on cardiac autonomic regulation and subsequent ventricular arrhythmias (VAs) in post-infarcted hearts. In order to explore the functions of sema 3A in post-infarcted hearts, lentivirus-Sema 3A-shRNA and negative control vectors were delivered to the peri-infarcted myocardium rats respectively. Meanwhile, recombinant sema 3A and control (0.9 % NaCl solution) were injected intravenously into infarcted rats to test the therapeutic potential of sema 3A. Results indicated that levels of sema 3A were higher in post-infarcted hearts compared with sham rats. However, sema 3A silencing leaded to sympathetic hyperinnervation, increased myocardial norepinephrine (NE) content and inducible VAs. Conversely, the intravenous administration of sema 3A to infarcted rats reduced sympathetic nerve sprouting, improved cardiac autonomic regulation, and decreased the incidence of inducible VAs. However, both infarct size and cardiac function were similar among infarcted hearts. The upregulation and administration of sema 3A exerted beneficial effects on infarction-induced cardiac autonomic disorders by increasing cardiac electrical stability and reducing VAs. Sema 3A might be a potential therapeutic agent for cardiac autonomic abnormalities induced arrhythmias.

1 March 2022 in Journal of Cardiology
Verified
Journal Article
Closed access
YWYe Wang
Ye Wang
CSChengying Shao
Chengying Shao
LQLei Qi
Lei Qi
JTJiayu Tan
Jiayu Tan
YZYuepeng Zhao
Yuepeng Zhao
SYSuhua Yan
Suhua Yan

10 June 2014 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
HHHesheng Hu
Hesheng Hu
MXMei Xue
Mei Xue
RXRui Xu
Rui Xu
XWXiao-Jun Wang
Xiao-Jun Wang
MCMing-You Chen
Ming-You Chen
SYSu-Hua Yan
Su-Hua Yan
Radiofrequency (RF) ablation is a widely accepted and ideal therapeutic tool to cure some tachycardias. The occurrence of complications varies depending on the procedure being performed. Sudden unexpected prolonged asystole is rare for most ablation procedures and the underlying mechanisms remain unclear.

1 May 2026 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
JYJian Ye
Jian Ye
YFYouqi Fan
Youqi Fan
YWYe Wang
Ye Wang
YJYifei Jian
Yifei Jian
YGYue Gao
Yue Gao
HHHesheng Hu
Hesheng Hu
Aim: To evaluate the cost-utility of pulsed field ablation (PFA) compared with radiofrequency ablation (RFA) and cryoablation, respectively, in Chinese patients with paroxysmal atrial fibrillation. Materials & methods: Patients with paroxysmal atrial fibrillation at different levels of atrial arrhythmia burden (<0.1%, 0.1–9.9%, ≥10%) may experience various atrial arrhythmia burden states after undergoing ablation. A decision tree model was developed to simulate this process from a healthcare perspective, where patients could undergo a repeat ablation or experience a nonfatal stroke. Transition probabilities, clinical outcome and quality of life data were obtained from published sources and confirmed by expert physicians. Cost data were estimated from a survey of clinicians at tertiary hospitals, based on actual clinical practices. The uncertainty of results was explored through one-way sensitivity analysis and probabilistic sensitivity analysis by Monte Carlo simulation. The secondary outcome, return on investment, was calculated from hospital administrator perspective, as net revenue divided by total cost of certain ablation type. Results: PFA demonstrated favorable cost–effectiveness compared with both RFA and cryoablation under the three-times China’s per capita GDP threshold. When compared with RFA, PFA yielded an incremental 0.016 quality-adjusted life years (QALYs) (0.859 vs 0.842) with an incremental cost–effectiveness ratio of ¥37,000 per QALY gained. This cost–effectiveness was primarily driven by savings of ¥1558 in weighted repeat ablation surgery costs and ¥506 in long-term medication costs for anti-arhythmic and anticoagulants. When compared with cryoablation, PFA resulted in an incremental 0.006 QALYs (0.859 vs 0.852) with an incremental cost–effectiveness ratio of ¥231,167 per QALY gained, mainly attributed to savings of ¥1300 in repeat ablation surgery costs and ¥133 in long-term medication costs. As a secondary outcome, PFA yielded a return on investment of 0.313. Conclusion: PFA was likely to be more cost effective than both radiofrequency ablation and cryoablation in China. The study suggests that PFA represents a high-value intervention that aligns superior clinical outcomes with favorable hospital financial sustainability, supporting its prioritized adoption in the management of atrial fibrillation in China.

20 April 2022 in Journal of International Medical Research
Verified
Journal Article
Open access
JYJie Yin
Jie Yin
YWYe Wang
Ye Wang
XLXiaolu Li
Xiaolu Li
MXMei Xue
Mei Xue
WCWenjuan Cheng
Wenjuan Cheng
SYSuhua Yan
Suhua Yan
A man in his early 40s developed palpitations brought on by swallowing and was found to have short runs of atrial tachycardia induced by swallowing solid food. Atrial tachycardia during swallowing was documented on electrocardiography and 24-hour Holter monitoring. No structural heart disease or esophageal disorders were found by echocardiography. The patient then underwent an electrophysiological study and catheter ablation. We mapped the left atrium with a multipolar mapping catheter while the patient swallowed bread and found that the earliest endocardial breakthrough was on the left anterior superior atrium, where the left superior ganglionated plexus was located. We successfully eliminated the paroxysmal atrial tachycardia at this site. Interestingly, in the process of ablation, atrioventricular node reentrant tachycardia was triggered. After the slow-pathway ablation procedure, no further tachycardia was induced.